Effect of plasma-derived or recombinant factor VIII on inhibitor development. A systematic review

被引：0
|
作者：
Iorio, A.
Halimeh, S.
Bidlingmaier, C.
Ettingshausen, C. E.
Gringeri, A.
Holzhauer, S.
Knoefler, R.
Kreuz, W.
Kurnik, K.
Manner, D.
Santagostino, E.
Mannucci, P. M.
Nowak-Goettl, U.
机构：
来源：
HAEMOPHILIA | 2010年 / 16卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：410 / 410
页数：1
相关论文
共 50 条
  • [31] Rates of Inhibitor Development in Previously Untreated Patients with Severe Hemophilia A Treated with Plasma-Derived or Recombinant Factor VIII: No Proof of Difference or Proof of No Difference?
    Messori, Andrea
    Fadda, Valeria
    Maratea, Dario
    Trippoli, Sabrina
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2014, 40 (02): : 269 - 270
  • [32] RECOMBINANT AND PLASMA-DERIVED FACTOR-VIIA DO NOT CORRECT BLEEDING-TIME IN A RABBIT FACTOR-VIII INHIBITOR MODEL
    TURECEK, PL
    SCHWARZ, HP
    THROMBOSIS AND HAEMOSTASIS, 1995, 73 (06) : 986 - 986
  • [33] Trial Results Reveal Greater Risk of Inhibitor Formation in Patients With Hemophilia A Receiving Recombinant Factor VIII Than in Patients Receiving Plasma-Derived Factor VIII
    不详
    AMERICAN JOURNAL OF MANAGED CARE, 2016, 22 : 20 - 21
  • [34] The increased demand for plasma-derived factor VIII in Italy
    Arcieri, Romano
    Calizzani, Gabriele
    Candura, Fabio
    Mannucci, Pier Mannuccio
    BLOOD TRANSFUSION, 2017, 15 (03) : 279 - 280
  • [35] Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates
    Dingli, D
    Gastineau, DA
    Gilchrist, GS
    Nichols, WL
    Wilke, JL
    HAEMOPHILIA, 2002, 8 (05) : 629 - 634
  • [36] Response to "Rates of Inhibitor Development in Previously Untreated Patients with Severe Hemophilia A Treated with Plasma-Derived or Recombinant Factor VIII: No Proof of Difference or Proof of No Difference?"
    Franchini, Massimo
    Mengoli, Carlo
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2014, 40 (02): : 271 - 272
  • [37] Multicenter comparison of inhibitor (Inh) development on plasma-derived (PD) vs recombinant (rec) factor VIII(fVIII) in severe hemophilia a patients (sHA pts).
    DiMichele, D
    Rothschild, C
    Sultan, Y
    Kroner, B
    Aledort, L
    BLOOD, 1999, 94 (10) : 238A - 238A
  • [38] Inhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH study
    Miri, Syna
    Rosendaal, Frits R.
    Kavakli, Kaan
    Eshghi, Peyman
    Moghaddam, Soha Mohammadi
    Scardo, Sara
    Habibpanah, Behnaz
    Elalfy, Mohsen
    Halimeh, Susan
    Nicolo, Gabriella
    Gokcebay, Dilek
    Ozbek, Namik
    Celkan, Tiraje
    Mohammadi, Ahmad
    Karimi, Mehran
    Shahsavani, Amin
    Yilmaz, Baris
    Albayrak, Canan
    Gunes, Burcak
    Kaya, Zuehre
    Ay, Yilmaz
    Akbayram, Sinan
    Sarper, Nazan
    Mannucci, Pier Mannuccio
    Peyvandi, Flora
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2024, 8 (08)
  • [39] Plasma-derived or recombinant factor VIII products and inhibitors in previously untreated patients with severe hemophilia
    van der Bom, Johanna G.
    Gouw, Samantha C.
    van den Berg, H. Marijke
    BLOOD, 2007, 110 (03) : 1074 - 1075
  • [40] Lower inhibitor risk of plasma-derived factor VIII concentrates versus recombinant factor VIII concentrates in patients with severe haemophilia A : result from SIPPET study and comments
    Biron-Andreani, Christine
    Diaz, Isabelle
    Navarro, Robert
    Schved, Jean-Francois
    HEMATOLOGIE, 2019, 25 (02): : 93 - 99
12345